Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs ...

The New York Times will take down Vertex on Aug. 29. By Everdeen Mason My favorite part of this job is creating new things. I love the feeling of laboring with a group of kindred spirits to make ...

Vertex Pharmaceuticals VRTX -1.88% has agreed to acquire Alpine Immune Sciences ALPN 0.02% for $4.9 billion in cash, bolstering its portfolio on kidney diseases as deals in biotechnology continue ...

Vertex reported first-quarter adjusted earnings per share of $4.06, down from $4.76 a year ago, missing the consensus of $4.32. The cystic fibrosis-focused company reported sales of $2.77 billion ...

Vertex sees 2025 revenue of $11.75 billion to $12.0 billion, the midpoint of which is above analysts' average expectation of $11.84 billion, according to data compiled by LSEG.

Vertex doesn't pay a dividend at present, which is unusual among the "Big Pharma" sector. However, its stock is up nearly 60% on a five-year basis, and remarkably, up >150% since October 2021.

Vertex Pharmaceuticals and CRISPR Therapeutics received regulatory approval for the first gene-editing therapy using CRISPR technology in the U.S. The treatment, called Casgevy, is used to treat ...